Pediatric acute myeloid leukemia outcomes after conventional treatment;Perspectivas para a leucemia mielóide aguda na infância após a observação de um grupo de pacientes tratados convencionalmente

Revista Brasileira de Hematologia e Hemoterapia

Volumn 28, Issue 4, 2007, Pages 246-252

  Zanichelli, Maria Aparecida ^a,b   Cristófani, Lilian Maria ^a   Almeida, Maria Tereza A ^a   Maluf Jr , Paulo T ^a   Odone Filho, Vicente ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL BRIGADEIRO   (Brazil)

^c Unidade de Oncologia   (Brazil)

Author keywords

Acute myeloid leukemia; Allogeneic bone marrow transplantation; Conventional treatment; Pediatric age

Indexed keywords

EID: 34547303314     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1996. CA Cancer J Clin 1996;46:5-27.
2. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 1948; 28:787-93.
3. Balis FM, Holcenberg JS, Poplack DG. General principles of chemotherapy. In: Pizzo PA & Poplack DG, eds. Principles and practice of Pediatric Oncology. 3rd ed. Philadelphia: Lippincott-Raven; 1997. p.215-72.
4. Brandalise S, Odone Filho V, Pereira WV, et al. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and GBTLI-85. Leukemia 1993; 7(Supl. 2):S142-S145.
5. de Camargo B, Franco EL (for the Brazilian Wilms' Tumor Study Group). A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms' tumor. Cancer 1994;73:3.081-6.
6. Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematol Oncol 1995;17:185-97.
7. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62.
8. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trial conducted between 1981 and 2000. Leukemia 2005;19:2.101-16.
9. Entz-Werle N, Suciu S, van der Werff Ten Bosch J et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia 2005;19:2.072-81.
10. Tallman MS. Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice. Cancer Treat Res 2004;121:45-67.
11. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the classification of acute leukemias. Br J Haematol 1976;33:451-8.
12. Bene MC. Immunophenotyping of acute leukaemias. Immunol Lett 2005;98:9-21.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. nd ed. London: British Medical Association; 1977.
15. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
16. Mayer RJ. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol 1987;14:384-96.
17. Buckley JD, Lampkin BC, Nesbit ME, et al. Remission induction in children with non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Group Study. Med Pediatr Oncol 1989;17:382-90.
18. Dahl GV, Kalwinsky DK, Murphy S, et al. Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. Blood 1982;60:856-63.
19. Wells RJ, Woods WG, Lampkin BC, et al. Impact of high dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Children's Cancer Study Group. J Clin Oncol 1993;11:538-45.
20. Capizzi RL, Poole M, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ara-C and asparaginase. Blood 1984;63:694-700.
21. Kalwinsky D, Mirro J Jr, Schell M, et al. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide. J Clin Oncol 1988;6:1.134-43.
22. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990;75:1.932-40.
23. Pui CH, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991;78:1.327-37.
24. Dahl GV, Simone JV, Hustu HO, et al. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer 1978;42:2.187-92.
25. Creutzig U, Ritter J, Zimmermann M, et al. Does cranial irradiation reduce the risk of bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 1993;11:279-86.
26. Pui CH, Dahl GV, Kalwinsky DK, et al. Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood 1985;66:1.062-7.
27. st ed. Boston: Blackwell Scientific; 1994. p.607-17.
28. Gluckman E, Rocha V. Cord blood transplantation for children with acute leukemia: an Eurocord registry analysis. Blood Cells Mol Dis 2004;33:271-3.
29. Viana MB, Cunha KCCMS, Ramos G, et al. Leucemia mielóide aguda na criança: experiência de 15 anos em uma única instituição. J Pediatr 2003;79:489-96.
30. Tiedemann K, Waters KD, Tavro GP, et al. Results of intensive therapy in childhood acute myeloid leukemia incorporating high dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 1993;82:3.730-8.
31. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1990;75:555-62.
32. Stein J, Dini G, Yaniv I. The hope and the reality of reduced intensity transplants in children with malignant diseases. Bone Marrow Transplant 2005;35(Supl. 1):S39-S43.
33. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukaemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304-12.
34. Roman E, Cooney E, Harrison L, et al. Preliminary results of the safety of immunotherapy with gentuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 2005;11:7164s-70s.
35. Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005;106:1.183-8.
36. Odone-Filho V, Carvalho A, Ramos RR, et al. Complete chimerism following the use of anti-CD33 antibody in a child with relapsed acute lymphocytic leukemia (ALL) after allogeneic bone marrow transplantation (allo BMT) (abstract [No 153] apresentado aos 2005 Tandem BMT Meetings, Keystone, CO, EUA). Biol Blood Marrow Transplant 2005;1(Supl. 2):58.
37. Adler A, Chervenick PA, Whiteside TL, et al. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988;71:709-16.
38. Robinson N, Sanders JE, Beyunes MC, et al. Phase I trial of interleukin-2 after unmodified bone marrow transplantation for children with acute leukemia. Blood 1996;87:1.249-54.
39. Siievers EL, Lange BJ, Sondel PM, et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. J Clin Oncol 1998;16:914-9.
40. Santana VM, Mirro J Jr, Kearns C, et al. 2-Clorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992;10:364-70.
41. Santana VM, Hurwitz CA, Blakeley RL, et al. Complete remissions induced by 2-Clorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994;84:1.237-42.
42. Cristofani LM, Vianna S, Pereira WV, et al. Childhood acute myeloid leukemia (AML): International Outreach-97 protocol (IO-97) results. Proceedings of ASCO 2003; v. 22. p. 808. r. 3.249.
43. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-8.
44. Kalwinsky DK, Raimondi SC, Schell MJ, et al. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 1990;8:75-83.
45. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;78:1.704-9.
46. Golub TR, Weinstein HJ, Grier HE. Acute myelogenous leukemia. In: Pizzo PA, Poplack DG, eds. Principles and practice of Pediatric Oncology. 3rd ed. Philadelphia: Lippincott-Raven; 1997. p.463-82.
47. Lange B, Gibson B. Acute myeloid leukemia. In: Education Book/International Society of Paediatric Oncology. XXXVII Congress of the SIOP, Vancouver, British Columbia, Canada 2005. p.79-86.